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BACKGROUND:  Rasopathies are developmental disease caused by mutations in genes 
encoding for signal transducers of the RAS-MAPK cascade. The aim of the present study was 
to provide a comprehensive description of morbidity and mortality in patients with 
molecularly confirmed Rasopathy. 
METHODS: A multicentric, observational, retrospective study was conducted in seven 
European cardiac centres participating to the CArdiac Rasopathy NETwork (CARNET). 
Clinical records of 371 patients with confirmed molecular diagnosis of RASopathy were 
reviewed. Mortality was described as crude mortality, cumulative survival and restricted 
estimated mean survival. Multivariable regression analysis was used to assess the impact of 
mutated genes on number of interventions and overall prognosis.  
RESULTS: Cardiac defects occurred in 80.3% of cases, almost half of them underwent at 
least one intervention. Overall, crude mortality was 0.29/100 patients-year. Cumulative 
survival was 98.8%, 98.2%, 97.7%, 94.3%, at 1, 5, 10, and 20 years, respectively. Restricted 
estimated mean survival at 20 years follow-up was 19.6 years. Ten patients died (2.7% of the 
entire cohort; 3.4% of patients with cardiac defect). Patients with hypertrophic 
cardiomyopathy (HCM) and age < 2 years or young adults, as well as subjects with 
biventricular obstruction and PTPN11 mutations had a higher risk of cardiac death.  
CONCLUSIONS: The risk of intervention was higher in individuals with Noonan syndrome 
and pulmonary stenosis carrying PTPN11 mutations. Overall, mortality was relatively low, 
even though the specific association between HCM, biventricular outflow tract obstructions 
and PTPN11 mutations appeared to be associated with early mortality, including immediate 




RASopathies are a group of disorders, caused by mutations in genes encoding for 
signal transducers of the RAS-MAPK cascade, affecting 1 in 1000-2500 children [1-4]. 
Among these disorders, Noonan syndrome (NS), NS with multiple lentigines (NSML, also 
known with the acronym LEOPARD syndrome), Costello syndrome (CS), and 
cardiofaciocutaneus syndrome (CFCS) share a similar systemic phenotype, with a wide 
spectrum of congenital heart disease (CHD) and hypertrophic cardiomyopathy (HCM) as 
major associated features [5-10]. Genotype-phenotype correlations have been established, 
including pulmonary stenosis (PS) and PTPN11 mutations, HCM and RAF1, HRAS and a 
subset of PTPN11 mutations, and mitral valve defects (MVD) and SHOC2 c.4A>G change 
[11-15]. 
To date, limited information is available on genotype, phenotype and clinical/surgical 
outcomes in these patients. The aim of this study was to extend the present knowledge on 
patients with RASopathies, providing data on molecular diagnosis and heart involvement, 
with a comprehensive assessment of morbidity and mortality, focusing on the impact of the 
genotype on the clinical outcome.   
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2. METHODS 
2.1 Study design and population 
This is a multi-centric, retrospective, observational study conducted in seven cardiac 
centres (Italy and UK) with expertise in RASopathies and participating in the CArdiac 
Rasopathy NETwork (CARNET). We retrospectively analysed clinical records of all patients 
with molecularly confirmed diagnosis of NS, NSML, CS or CFCS, followed up until July, 
2014. Molecular diagnosis was performed through a combination of Sanger sequencing and 
targeted resequencing directed to scan the entire coding sequence of CBL, PTPN11, SOS1, 
KRAS, HRAS, NRAS, SHOC2, RAF1, BRAF, MAP2K1 and MAP2K2 genes, which had been 
recognized as RASopathy disease genes at the time of this study [1]. 
The following data were collected: date of birth and sex; clinical diagnosis and 
mutation; clinical phenotype; type of heart defect, including PS, atrioventricular canal defects 
(AVC), HCM, and other less common defects, such as atrial septal defects (ASD) and mitral 
and aortic valve diseases (MVD and AVD, respectively); timing and details of all cardiac 
procedures; date and cause of death, when appropriate. Data were centralized in a unique 
database. The study protocol was approved by the Bambino Gesù Children’s Hospital’s 
Ethical Committee (Protocol Number 605.13) and by the Ethical Committees of all the other 
participating centres. 
 
3. STATISTICAL ANALYSIS 
Data were presented as median and range, mean ± standard deviation (SD), or 
percentages and CI, as appropriate. Mortality was described as crude mortality.  
Cardiac defects taken into account in the analyses were HCM, PS, and AVC; the 
other cardiac defects were grouped in the category “other heart defects” (OHD) and 
investigated only descriptively. 
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Similarly, in the descriptive analysis, rarer mutations with low recurrence in the 
cohort (i.e. CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, and SHOC2) were reported as 
“other genes” (OG), but were considered as single genes in the regression analyses. 
Logistic regression models where used to study how categorical variables 
(syndrome, presence of any cardiac defect and presence of a specific cardiac defect) were 
associated with each gene mutation; these analyses were adjusted for sex of the patients. 
Through Poisson regression, we studied: 
- the association between mutated genes and number of procedures received by 
each patient with a cardiac defect (interpreted as a count variable), adjusting for sex, presence 
of PS, HCM, AVC or OHD, and natural logarithm of years of follow-up 
- the association of each syndrome with number of interventions, adjusting for sex, 
type of heart defect and natural logarithm of years of follow-up; 
- the association between presence of PS, HCM, AVC and OHD, and the number of 
interventions, correcting for sex, gene, and natural logarithm of years of follow-up. 
Kaplan-Meier (KM) curves were used to describe the incidental risk of intervention 
and mortality, stratified by time, for each mutated gene, syndrome and heart defect; 95% 
confidence intervals (95% CI) are shown for the cumulative survival KM plots.  
In the population of subjects with heart defects, Cox proportional hazards models 
were used to assess the effect of having a mutated gene, a syndrome or a specific heart defect 
on the risk of intervention, respectively adjusting for sex and heart defect, sex and heart 
defect, sex and gene. 
The effect sizes of the regression models are reported as adjusted incidence rate 
ratios (aIRR) for Poisson regressions, and as adjusted hazard ratios (aHR) for Cox 
regressions. 
Poisson regression estimates were regularized using a Bayesian approach (Data In 
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Brief, table and statistical analysis). Bootstrap analysis was used to generate bias-corrected 
accelerated bootstrap confidence intervals (BCA CI 95%) and standardized effect sizes (sES) 
for all regression coefficients. 
KM models were also used to describe mortality as cumulative survival at 1, 5, 10  
and 20 years, as restricted estimated mean survival (on a 20-year follow up) and as function 
of mutated gene, clinical syndrome and specific cardiac defect. 
KM plots are used to visualize KM models; forest plots reporting effect sizes and 
BCA CI 95% are presented for each regression analysis. In the plots, only the main genes 
(BRAF, PTPN11, RAF1 and SOS1) were considered. 
The software R ver. 3.2.0 was used for analysis and plotting. See Data In Brief, for 
a more complete description of every analyses and of the statistical techniques used.  
 9 
4. RESULTS 
4.1 Study population and heart defects 
We enrolled 371 individuals with a RASopathy, including 297 (80.1%) with a clinical 
diagnosis of NS, 45 (12.1%) with NSML, 22 (5.9%) with CFCS, and 7 (1.9%) with CS. One 
hundred sixty-five patients (44.5%) were females. Median age at last follow-up was 8.75 
years (range 11 days-47.6 years). The date of birth was missing for 2 patients and the date of 
the last follow-up was missing for 33 subjects. Table 1 reports demographic, clinical and 
molecular characteristics of included patients. Data in Brief, Table 1 shows the distribution of 
the affected genes by syndrome. Of note, one patient, carrying a missense mutation in HRAS 
mutation (p.Gly13Asp) rarely occurring in CS, was diagnosed as affected by NS based on his 
clinical features, in line with a recent report [16]. This patient was not affected by heart 
disease.  
Two hundred ninety-eight patients (80.3%) had a cardiac involvement, either with a single 
anomaly or multiple defect(s). More than a half subjects had PS (59%), mostly isolated (81% 
of all patients with PS). Eighty-one (27%) had HCM; among these, 32% also had MVD 
and/or AVD. Other defects frequently reported included ASD (11%), AVD (10%), VSD 
(4.7%), AVC (4.4%). Tetralogy of Fallot, aortic coarctation, coronary anomalies and patent 
duct arteriosus were reported in 3% of the patients (Table 1).  
 
4.2 Morbidity 
Among all patients with CHD, 141 (47.3%) underwent at least one surgical procedure 
or catheter intervention. Fifty-eight patients (41.1% of patients who underwent the first 
procedure) needed a second intervention, the majority (approx. 60%) being patients affected 
by PS, who underwent a second procedure after a first, unsuccessful treatment (85% of cases, 
mainly after primary percutaneous balloon pulmonary valvuloplasty (PBPV)).  In 7 patients 
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(12%), a significant pleural or pericardial effusion was the reason for an early reintervention 
(Data in brief, Figure 1). 
Genes 
We analysed the association between each mutated gene and number of interventions 
(adjusting for sex, cardiac defect and length of follow up), including both interventional and 
surgical procedures (Data in Brief, Table A and Figure 2A). Individuals heterozygous for 
BRAF mutations had a significantly lower number of interventions compared to patients with 
mutations of other genes. (aIRR: 0.448, BCa 95% CI: [0.158, 0.859]) 
According to the KM curves (Figure 1A), PTPN11 mutations increased the risk of 
early intervention, the curves showing the strongest difference around 15 years of age. This 
difference was no longer observed at 20 years of age. Patients with BRAF mutations 
underwent interventions later, compared to those with heterozygous mutations of other genes. 
RAF1 and SOS1 did not show a clear difference in terms of risk of intervention. However, the 
Cox analysis did not show a significant effect on hazard of intervention for any of the disease 
genes, if the effect of the cardiac defect was taken into account (Data In Brief, Table B and 
Figure 2B). 
Syndromes 
Poisson regression (adjusting for sex, type of cardiac defect and length of follow up), 
showed that subjects with CFCS had a significantly lower number of interventions (aIRR 
0.264, BCa95% CI: [0.0767, 0.909]), while NS was associated with a significantly higher 
number of interventions compared to other syndromes (aIRR 1.88, BCa95% CI: [1.19, 3.17]) 
(Data In Brief, Table C and Figure 2C).  
Kaplan-Meier curves showed that NS was associated with a persistently higher risk of 
intervention (Figure 1B); CFCS patients had a lower risk of intervention, although the 
population was very small. Of note, NSML seemed to be positively associated with an 
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overall reduced cumulative risk of intervention, although this effect tended to decrease 
towards adulthood. CS population was too small to draw conclusions.  
Cox analysis confirmed that NS was associated with a higher cumulative risk of 
interventions, independently from the type heart defect (aHR 2.13, BCa95% CI: [1.12, 3.75]) 
(Data In Brief, Table D and Figure 2D). 
Heart defects 
Subjects with PS (aIRR 2.55, BCa95% CI: [1.59, 3.9]) and AVC (aIRR 3.86, BCa95% 
CI:[2.37, 6.08]) had a significantly higher number of interventions (when adjusting for sex, 
mutated gene, cardiac defect and length of follow up, Data In Brief, Table E and Figure 2E).  
Kaplan-Meier curves showed that PS and AVC had a consistently higher risk of earlier 
intervention (Figures 1C and 1D) and HCM had a reduced risk of intervention compared to 
patients affected by other defects. In patients with HCM, the lower risk of intervention 
disappeared at around 15-20 year of age (Figure 1E). Cox analysis (Data in Brief, Table F 
and Figure 2F) confirmed the risk of an earlier intervention for PS (aHR 2.93, BCa95%CI: 
[1.47, 5.36]) and AVC (aHR 6.12, BCa95% CI: [2.62, 13.6]). 
 
4.3 Mortality 
Crude mortality was 0.29/100 patients-year. Cumulative survival was 98.8%, 98.2%, 
97.7%, 94.3%, at 1, 5, 10, and 20 years respectively. Restricted estimated mean survival at 20 
years of follow-up was 19.6 years (Figure 2A). Kaplan-Meier curves for risk of mortality are 
reported by gene (Figure 2B), syndrome (Figure 2C) and type of heart defect (Figure 2D, 2E, 
2F). 
Ten patients died (2.7% of the entire cohort; 3.4% of patients with cardiac defect). Six 
subjects died during the first 2 years of life. Among them, two patients died from leukaemia. 
Both were affected by NS and carried PTPN11 mutations, with ASD and HCM respectively. 
 12 
For the remaining 8 patients, death occurred due to cardiac causes. Specifically, two patients, 
both affected by HCM and heterozygous for a PTPN11 mutation, died before 2 years of age 
from sudden death, before receiving any surgical treatment. Of these, one was affected with 
NS and had a severe subaortic obstruction associated with the HCM, while the other patient 
was affected with NSML and had a biventricular obstruction due to concomitant muscular 
subaortic and severe pulmonary valve stenosis. The remaining six patients underwent at least 
one procedure. Of these, two patients died for late complications during the post-operative 
follow up. Both these patients were affected by HCM and had a PTPN11 mutation. One 
subject (NS) died from rejection eight months after heart transplantation. The other patient 
(NSML), with a biventricular outflow tract obstruction, underwent multiple surgical 
treatment for a pulmonary stenosis, and died from sudden death more than 5 years after 
surgery. The remaining 4 patients died from immediate post-operative complications within 
30 days from the intervention. One patient (NS, PTPN11), affected with partial AVC and 
aortic valve stenosis, died from a cardiac tamponade after a second intervention in which he 
received aortic root replacement with coronary reimplantation. He had previously undergone 
aortic valvulotomy and AVC correction as first intervention. One patient who was born 
preterm (34 weeks of gestational age; NS, PTPN11 mutation) and had with severe pulmonary 
stenosis and severe aortic stenosis, died from low cardiac output following a surgical 
pulmonary valvulotomy. He had previously received an unsuccessful balloon pulmonary 
dilation. Finally, two patients, one with NS-like features (so called Mazzanti syndrome due to 
the recurrent c.4A>G mutation in SHOC2) [15], and one with NSML, associated with a 
mutated PTPN11 allele, both affected with HCM and severe left and right outflow tract 
obstruction, died from low cardiac output following a surgical intervention aimed at reducing 
biventricular outflow obstructions. MVD, AVD and biventricular obstruction were frequent 
in the group of patients who died, particularly in the subgroup of patients who died for 
 13 
immediate post-surgical complications. Table 2 shows molecular and clinical details for each 




In this study, we retrospectively analysed a large cohort of patients affected by 
RASopathies with a confirmed molecular diagnosis. Heart involvement, morbidity and 
mortality were analysed taking into account both the involved disease genes and the clinical 
diagnosis. Our results show that patients affected by RASopathies have an overall good 
cumulative survival (94.3% estimated survival at 20 years), along with a higher risk for 
cardiac events in infants (<2 y.o.) and young adults with PTPN11 mutations.  
 
5.1 Prevalence and clinical significance of heart defects 
As expected since the relatively higher proportion of subjects with NS, PS was the 
most common heart defect in our study population, followed by HCM and ASD. These 
results are consistent with those reported in a recent study by Prendiville [17] (which 
however included only patients with NS) and by Lin et al., who found a high prevalence of 
PS and HCM in a population including NS, NSML, CS and CFCS [18]. Consistently with 
previous reports, MVD and AVD also recurred as associated features in NS and NSML 
patients [19,20], as isolated defects or as part of the AVC or obstructive HCM spectrum. 
When associated with AVC or HCM, AVD and MVD represent a marker of phenotypic 
complexity and severity, deserving a comprehensive diagnostic evaluation and careful 
consideration for a tailored surgical approach [18-22].  
  
5.2 Morbidity 
Among patients affected with a heart disease, almost half underwent a percutaneous 
and/or surgical intervention. A second intervention was frequent (more than 40% of patients 
that underwent a first intervention).  
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As expected, individuals with AVC were those who most frequently required an early 
intervention, followed by NS patients with PS and PTPN11 mutations. As shown by the KM 
curves, patients affected by PS and NS displayed a need for a surgical/percutaneous 
intervention throughout the entire time of follow-up. In the subgroup of patients who 
underwent a second procedure, the main cause for reintervention was recurrence of PS (60% 
of these patient), mainly for an unsuccessful PBPV. These results are in agreement with 
previous studies who reported an intervention in a half of their NS population, with 65% of 
patients requiring additional interventions [17]. Similarly, McCrindle et al. reported a 
significant need for reintervention in patients with PS after PBPV, due to the specific 
morphology of the pulmonary valve in these patients, characterized by dysplastic pulmonary 
leaflets [23].  
Regarding patients with HCM, our study suggests that the risk of intervention in these 
patients is lower after the first years and before 15-20 years of age, in line with Prendiville et 
al. and Poterucha et al. [17,24]. In patients with HCM and NS with a symptomatic left 
ventricular outflow obstruction requiring an intervention, myectomy has been demonstrated 
as feasible and a practical alternative to heart transplant [17,24]. We reported MVD as a 
marker of clinical complexity in HCM patients. Maron et al. recently reported that the length 
of the mitral valve leaflet is significantly increased in HCM patients compared with age, sex 
and body size-matched controls without cardiovascular involvement [25]; structural mitral 
valve abnormalities should be regarded as a primary phenotype of HCM also in patients with 
NS [19]. These characteristics may help to explain the pathophysiology of the subaortic 
gradient in patients with obstructive HCM with mild septal hypertrophy and its potential role 
in surgical and/or morbidity outcome.  
Subaortic stenosis due to accessory fibrous connective tissue and/or anomalous 
insertion of the mitral valve or anomalous left ventricle papillary muscle, should be carefully 
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taken into account regarding morbidity and mortality, also in patients with AVC, particularly 
in RASopathies [19-21,26]. We noticed that the surgical approach aimed at relieving left and 
right ventricular stenosis could be very difficult or unsuccessful in infants and neonates with 
severe HCM consisting in biventricular outflow tract obstruction.  
In our cohort, patients with classic NS phenotype were most likely to receive a higher 
number of percutaneous or surgical interventions, while CFCS patients received a lower 
number of interventions, in agreement with the negative association between BRAF and the 
risk of reintervention.  
Finally, a significant cause of reintervention (more than 10%) was post-procedural 
pericardial or pleural effusion. Our results are in agreement with previous findings in patients 
with RASopathies [17,27]. The higher risk of pericardial or pleural effusion may be due to 
specific lymphatic anomalies reported in patients affected with these syndromes. 
                      
5.3 Mortality 
Mortality is relatively low in patients affected by RASopathies. We observed a 
mortality of 2.7% in the entire cohort, and of 3.4% among patients with cardiovascular 
involvement. Overall, our data document that heart defects and associated complications 
were the most recurrent cause of death in our RASopathy cohort. Of note, 80% of patients 
died for a specific cardiac cause, e.g. post-operative low cardiac output, sudden death or heart 
transplant rejection. In particular, NSML or NS patients with HCM, due to PTPN11 gene 
mutations, were at higher risk of cardiac death. Indeed, out of 7 patients with HCM 
associated with NS or NSML, 6 died for cardiac causes (of these, 3 died before 2 years of 
age). 
Seven patients in the group of patients who died received at least one intervention. 
Five of them underwent a further procedure. Immediate post-operative complications were 
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cause of death in 4/7 cases. Interestingly, all these patients had an associated MVD/AVD, 
suggesting the possible role of these additional cardiac malformations in worsening the 
clinical expression the heart defects [19,21,25,26]. In the subgroup of patient who died for 
cardiac causes, biventricular outflow tract obstruction was frequent (5/8 patients), in 
association with HCM or CHD, and can therefore be considered as a surgical risk factor.  
When analysing the age distribution of the patients who died, we found that the 
majority of deaths occurred in the first two years of life, or among young adults (> 20 years 
of age). Prendiville et al. reported a mortality of 15% in patients with NS and HCM [17], 
while mortality of patients with RASopathies and HCM was 9% in this survey. Data from the 
Pediatric Cardiomyopathy Registry showed that crude mortality was worse in syndromic 
HCM (mainly, NS) compared to non-syndromic HCM [28,29]. Specifically, Colan et al. 
showed that children with syndromic HCM and with an early onset HCM phenotype (<1 year 
of age) had a poor prognosis, with a 5-year survival of 65.8% [28]. Wilkinson et al. showed 
the importance of heart failure at HCM onset as a risk marker of prognosis, with a one-year 
survival in 31% of patients [29]. Limongelli et al. suggested that patients with NSML and 
HCM require a periodic and careful cardiac risk assessment due to the frequent occurrence of 
life-threatening arrhythmias and sudden death [22].  
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6. STUDY LIMITATIONS 
The retrospective design of the study represents as per se a limitation. Recently discovered 
genes, e.g. RIT1, SOS2 and LZTR1 [30,31], have not been tested in our cohort, therefore 
excluding from our population RASopathy patients with negative genetic characterization 
may have biased our results. Another limitation concerns the statistical analysis. Some 
variables (e.g. patients with RAF1 gene mutation, CS syndrome, those who received more 
than two reinterventions, deceased patients), had a very low numerosity, and this could have 
impaired the precision of the analysis. However, using the bootstrap and a Bayes-based 
regularization, we increased the sensitivity of the analysis. 
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7. CONCLUSIONS 
This multicentric study, based on a large cohort of patients with molecular confirmed 
diagnosis of RASopathy, provides specific information on cardiac morbidity and mortality in 
these patients. Cardiovascular involvement is a common feature of these disorders. 
Percutaneous or surgical intervention is required in almost half of the individuals affected by 
RASopathies, particularly in subject with NS and PS while, the number of interventions is 
considerably lower among those with CS and CFCS. Cardiac mortality is relatively 
uncommon in these disorders. However, the association between HCM (particularly, if 
biventricular obstruction coexists), PTPN11 mutations and NSML, with a peculiar 
distribution of age (infants and young adults), seems to represent a risk factor for surgical 
mortality or sudden death.  
Defining “red flags” for a more severe cardiac phenotype spectrum will be essential to 
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Figure 1. Kaplan-Meier curves reporting changes in number of years free of surgical 
intervention by gene (A), syndrome (B) and specific heart defects (C to E). 
Figure 2: Kaplan-Meier curves reporting estimated years of survival, overall (A) and by gene 
(B), syndrome (C) and specific heart defects (D to F). 
  
